Traditional insulin replacement therapy involves multiple daily insulin injections or the delivery of insulin by a pump, the need for careful blood glucose monitoring, and the fear of an unwanted fall in blood glucose (hypoglycemia). Fear of hypoglycemia prevents optimal glycemic management leading to long-term hyperglycemia and damage to the body (kidney, heart, extremities).
Abvance is a biotechnology company developing a new insulin: glucagon formulation called ABV100 for preventing hypoglycemia. Patients who use ABV100 instead of insulin will experience improved blood glucose control with a safety buffer against hypoglycemia. In addition, ABV100 does not require new behavioral changes or devices and will lighten the daily burden of disease management.
ABV100: A titratable, fixed ratio combination of two FDA-approved peptides to control glycemia while mitigating the threat of hypoglycemia.
Company Details
- Employees
- 9
- Address
- Reno, Nv, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- abvancetherapeutics.com
- Keywords
- diabetes, insulin, hypoglycemia.
- HQ
- Reno, NV
Abvance Therapeutics Questions
Abvance Therapeutics's website is abvancetherapeutics.com
Abvance Therapeutics's LinkedIn profile is https://www.linkedin.com/company/abvance-therapeutics
Abvance Therapeutics has
9 employees.
View email and phone details for 9
employees at Abvance Therapeutics.
Abvance Therapeutics's industry is
Biotechnology Research
Abvance Therapeutics's top competitors are
Artelo Biosciences, Inc.,
Vor Bio,
Pep2tango Therapeutics,
Cidara Therapeutics,
Primera Therapeutics,
Channel Therapeutics,
Mainz Biomed,
Hibiscus Bioventures,
Abvance,
Morphiex Biotherapeutics.
Abvance Therapeutics's categories are Biotechnology Research
